On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridayMar 10, 2017 10:25 am

NetworkNewsBreaks – Singlepoint, Inc. (SING) CEO Discusses Company’s Activity in the Cannabis Industry on MoneyTV

Full-service mobile technology and marketing provider Singlepoint, Inc. (OTC: SING) is a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” To view the show, visit www.MoneyTV.net. In this week’s episode, Singlepoint CEO Greg Lambrecht discusses the company’s growing presence in the legal cannabis market. “While we’re waiting for the banks to open up, we’re finding other products that we can put in the dispensary. If you go to our SingleSeed.com site, you can see the stats specifically for dispensaries. So there’re really a…

Continue Reading

ThursdayMar 09, 2017 2:23 pm

NetworkNewsBreaks – The Singing Machine Company, Inc. (SMDM) Enters Distribution Agreement with Alliance Entertainment

The Singing Machine Company, Inc. (OTCQX: SMDM), the North American leader in consumer karaoke products and a member of the 2017 OTCQX® Best 50, this morning announced its entry into a new distribution partnership agreement with Alliance Entertainment, a leading wholesale distributor of music, movies and consumer electronics servicing more than 2,000 independent music and video retailers. Through the new agreement, Alliance Entertainment will distribute SMDM’s Singing Machine and Singing Machine Kids product lines throughout its expansive retail distribution network, both domestically and internationally. “We are thrilled to be partnering with Alliance Entertainment to help us expand our reach into…

Continue Reading

ThursdayMar 09, 2017 11:16 am

NetworkNewsBreaks – Histogenics Corp. (NASDAQ: HSGX) Announces Publication of Data from Human Engineered Cartilage Testing; Shares Rise

Histogenics (NASDAQ: HSGX) this morning announced the online publication of biomechanical and structural data that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a sponsored research agreement between Histogenics and Dr. Lawrence Bonassar at Cornell University. This was the first study to use three mechanical tests to examine and understand the performance of repaired cartilage in accordance with FDA guidance. Data from the study demonstrate Histogenics’ tissue engineered cartilage constructs exhibit mechanical properties approaching native human cartilage as early as three weeks in culture and prior to implantation. “The data generated in this study…

Continue Reading

ThursdayMar 09, 2017 11:14 am

NetworkNewsBreaks – Medigus Ltd. (NASDAQ: MDGS) Shares Rally on First MUSE Procedure in China

Shares of Medigus (NASDAQ: MDGS) gained 25% pre-market, currently up 9%, after the medical device company announced the completion of the first MUSE procedure in China. The procedure was performed by Professor Rong Wan, Department of Gastroenterology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University. Professor Wan reported that the procedure was successful with the patient encountering minimal discomfort. The MUSE system is a single-use flexible transoral stapler that enables a single physician to perform an incisionless transoral fundoplication, the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD). "With the completion of our…

Continue Reading

ThursdayMar 09, 2017 11:10 am

NetworkNewsBreaks – Aegis Capital Raises Price Target on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)

Aegis Capital Corp. has raised its price target on Progenics Pharmaceuticals (NASDAQ: PGNX) to $14 from $11 with expectations of an accelerated adoption ramp for the company’s Azedra. On February 14, 2017, the company announced the commencement of enrollment in an investigator initiated phase 1 clinical trial with 131-I-MIP-1095 (1095) at MSK. Progenics recently conducted a phase 2b trial of Azedra, which has demonstrated tumor reduction despite the trials primary endpoint being reduction in anti-hypertensive medication. The company previously reported that 31.7% of patients reached the primary end point. “There is currently no alternative treatment for pheo-para, thus we believe…

Continue Reading

WednesdayMar 08, 2017 11:44 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 8, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CAPN 23.53% – News: Completes merger with Essentialis, Inc. BDCI 17.75% – News: Begins process to establish operations in Freeport, Bahamas CIIX 12.75% – News: Moving on momentum from recent increased price target by SeeThruEquity KTOV 7.72% – News: Signs License Agreement for KIT-302 in South Korea RGLS 7.72% – News: Litigation law firm announces class action lawsuit BIOC 7.08% – News: Presenting a corporate overview at the 29th Annual ROTH Conference on March…

Continue Reading

WednesdayMar 08, 2017 11:44 am

NetworkNewsBreaks – Innovus Pharma (INNV) Receives Notification to Commercialize Sensum+® in the EU; Shares Surge

Shares of Innovus Pharmaceuticals (OTCQB: INNV) are 41% higher mid-morning after the company said it has received the CPNP notification number required to commercialize Sensum+® in all 28 member countries of the European Union. Sensum+® is currently approved to be marketed and sold in 31 countries worldwide, including the United States, Europe, India and Morocco. The company also recently received the CPNP notification number to commercialize Zestra® in the EU on March 2, 2017.  “Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be…

Continue Reading

WednesdayMar 08, 2017 10:38 am

NetworkNewsBreaks – ParkerVision, Inc. (NASDAQ: PRKR) Shares Climb on Favorable Decision by PTAB in Final Qualcomm (NASDAQ: QCOM) IPR

Shares of ParkerVision, Inc. (NASDAQ: PRKR) are up 33% this morning on news the Patent Trial and Appeal Board (PTAB) has issued its latest favorable decision for the company in regard to the petitions for Inter Partes Review (IPR) filed by Qualcomm (NASDAQ: QCOM) against ParkerVision patents. Today’s news increases the favorable decisions for the company to over six out of the ten petitions originally filed. There are no further IPR’s challenging ParkerVision patents currently before the PTAB. “We continue to take positive steps forward in our Qualcomm proceedings and believe these results are indicative of the strength of ParkerVision’s…

Continue Reading

WednesdayMar 08, 2017 10:36 am

NetworkNewsBreaks – Heron Therapeutics, Inc. (NASDAQ: HRTX) Reiterated with ‘Buy’ Rating at Aegis Capital, PT Adjusted to $33

Aegis Capital has issued a 'Buy' rating and price target of $33 on shares of Heron Therapeutics, Inc.’s (NASDAQ: HRTX) stock. The biotech company most recently announced the inclusion of SUSTOL® as part of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Antiemesis Version 1.2017. FDA-approved SUSTOL was given the highest recommendation of evidence and consensus for use preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving HEC or MEC regimens. “The NCCN is an alliance of 27 leading cancer centers in the US, and this recommendation reaffirms our belief that Sustol extended-released will…

Continue Reading

TuesdayMar 07, 2017 3:43 pm

NetworkNewsBreaks – Intellipharmaceutics International (NASDAQ: IPCI) Reiterated with ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital Corp. has reiterated its ‘Buy’ rating and $8 price target on shares of Intellipharmaceutics International (NASDAQ: IPCI). The pharmaceutical company recently received final approval for its abbreviated new drug application for its generic equivalent of the branded product Glucophage® XR. Specifically, the U.S. Food and Drug Administration (FDA) approved metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths. The drug is indicated for use in the management of type 2 diabetes. The company also has eight other abbreviated new drug application candidates awaiting response from the FDA. To view the full press release, visit:…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217